CDTX

Cidara Therapeutics (CDTX) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov^[4], including 1 Phase 3^[1], 1 Phase 2^[2], 1 Phase 1^[3].

Trial NCT07159763^[5] evaluates CD388 Injection in Influenza with a target enrollment of 7500 participants.

No Form 4 insider filings for CDTX were recorded at the SEC in the past 30 days^[6].